TCTR20210531008尚未招募4 期
A randomized investigator-blind study evaluating the efficacy and safety of 0.005% trifarotene cream versus 0.05% VAA cream in the treatment of moderate facial acne.
Galderma Thailand0 个研究点目标入组 60 人开始时间: 2021年5月31日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •1.Male or female, 18-50 years of age
- •2.Participants who have been diagnosed with moderate acne at baseline visit
- •3.Participants must willingly give informed consent.
排除标准
- •1.Participants who have acneiform eruption (e.g., chloracne, drug-induced acne) or other facial inflammatory skin conditions precluding the acne assessment
- •2.Participants who have any uncontrolled or severe diseases or any medical or surgical conditions, such as polycystic ovarian syndrome, may interfere with the interpretation or compliance with the protocol
- •3.Participants who expose to excessive ultraviolet radiation within one month before the baseline visit or plan to expose intense UV during this trial
- •4.Participants who are unwilling to refrain from use of prohibited medication including topical (such as topical benzoyl peroxide, azelaic acid, or topical antibiotics) and systemic (such as systemic antibiotics, oral antiandrogens, or oral isotretinoin) medications affecting acne conditions during this trial
- •5.A pregnant woman or nursing or unable to use non-hormonal birth control
- •6.Participants who have a history of study drug allergy
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combinationwith Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Na?ve Patients with Chronic Hepatitis C Genotype 1 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1MedDRA version: 12.0Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-009608-38-ITF.Hoffmann-La Roche300
进行中（未招募）
1 期
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioEUCTR2009-009608-38-FRF.Hoffmann-La Roche300
进行中（未招募）
不适用
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioEUCTR2009-009608-38-ATF.Hoffmann-La Roche300
进行中（未招募）
不适用
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioChronic Hepatitis C Genotype 1 Virus Infection (Treatment-Naive Patients)MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-009608-38-DEF.Hoffmann-La Roche300
终止
4 期
A randomized, double-blinded study investigating the safety and efficacy of daily low-dose oral fluconazole versus weekly fluconazole in the treatment of chronic vulvovaginal candidiasisChronic vulvovaginal candidiasisSkin - Dermatological conditionsInfection - Other infectious diseasesRenal and Urogenital - Other renal and urogenital disordersACTRN12614001258640Royal North Shore Hospital200